— R&D expenses increased to $26.8 million from $23.4 million in the prior-year quarter.
— For full-year 2020, operating cash use is expected to be in the range of $125 million to $150 million and operating expenses are estimated to be between $135 million and $160 million.
— On February 18, 2020, the company announced that the U.S. Food and Drug Administration (FDA) had accepted and filed its new drug application (NDA) for the approval of oral, once-daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks.
— BioCryst expects Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to approve its berotralstat drug for the prophylactic treatment of HAE in the second half of 2020.
— BCRX stock rose about 7% in the pre-market trading session.